Navigation Links
ViroPharma Incorporated Reports First Quarter 2009 Financial Results
Date:4/29/2009

- Company Achieves Record First Quarter of Net Product Sales; Quarter Highlighted by Nearly $7 Million in Net Sales of Cinryze(TM) C1 Esterase Inhibitor (Human) -

EXTON, Pa., April 29 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the first quarter ended March 31, 2009.

  • First quarter 2009 adjusted net income of $11.5 million, and GAAP net loss of $59.2 million; the difference is primarily associated with $65 million non-cash write-off of goodwill;
  • $60 million in net product sales, including $6.7 million in net sales of Cinryze(TM) (C1 esterase Inhibitor [human]);
  • Working capital of $301 million as of the end of the first quarter of 2009, which includes cash and cash equivalents of $245 million; and
  • $45 million principal amount of its senior convertible notes repurchased for $21.2 million.

Net sales of Cinryze and Vancocin(R) were $60.2 million for the first quarter of 2009 as compared to $50.9 million for Vancocin only in the first quarter of 2008, representing 18 percent growth in net product sales.

The Company is reporting both GAAP Net income (loss) and adjusted results. Adjusted net income is GAAP Net income excluding (1) non-cash interest expense including portions related to the adoption of FSP APB 14-1 as described below; (2) amortization related to the acquisition of Lev Pharmaceuticals and Vancocin, and step up in inventory related to purchase accounting arising from our acquisition of Lev Pharmaceuticals, (3) stock compensation expenses, and (4) certain non-recurring events such as the goodwill write off arising from our book value being lower than our market capitalization at March 31, 2009, and gain on extinguishment of repurch
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
2. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. ViroPharma to Present at Three November Healthcare Conferences
5. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
6. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
7. ViroPharma to Present at Three October Healthcare Conferences
8. ViroPharma to Present at Three September Healthcare Conferences
9. ViroPharma To Acquire Lev Pharmaceuticals
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 6, 2015  Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company ... , Viveve,s Chief Executive Officer, and Scott Durbin , ... July 9, 2015. , , , DATE:    ... , , TIME:     , , , 12:15 PM ... , http://tinyurl.com/viveve   ,    ...
(Date:7/6/2015)... 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: ... Novella Clinical (Novella), to conduct the phase ... diagnosed glioblastoma. Novella is a full-service, global clinical research ... mid-sized oncology companies. The ICT-107 phase 3 trial will ... Europe and Canada ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... industry-leading products for use in applications such as animal waste reduction, bioremediation, ... plants and restaurant kitchen settings, announced today that it will be showcasing, ...
(Date:7/3/2015)... Houston, Texas (PRWEB) , ... July 03, 2015 ... ... search firm, highly-regarded by Fortune 500 companies and professional service industries alike-- typically ... aimed to make clients laugh, honor a good cause and break from their ...
Breaking Biology Technology:Viveve to Webcast Live at VirtualInvestorConferences.com 2Viveve to Webcast Live at VirtualInvestorConferences.com 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2DryLet to Highlight Benefits of Patented ManureMagicâ„¢ at North American Manure Expo in Chambersburg, PA July 14-15, 2015 2The Alexander Group Declares Their Independence with a Bit of Levity 2
... activity in breast cancer patients with high expression of ... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... cancer, inflammation and autoimmune diseases, presented data from a ... in combination with the chemotherapeutic docetaxel in patients with ...
... online store offering cryogenic freezer storage boxes directly to labs at ... ... 31, 2009 -- A box maker, Wildcat Wholesale LLC, is selling ... guaranteed low prices. Cryovial boxes sold directly to labs make ...
... ultra-powerful laser can turn regular incandescent light bulbs into ... The process could make a light as bright as ... bulb while remaining far cheaper and radiating a more ... process creates a unique array of nano- and micro-scale ...
Cached Biology Technology:Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 2Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 3Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 4Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 5Box maker, Wildcat Wholesale, Makes Cryogenic Freezer Storage Boxes Affordable By Selling Directly To Labs 2Regular light bulbs made super-efficient with ultra-fast laser 2Regular light bulbs made super-efficient with ultra-fast laser 3
(Date:6/17/2015)... and HILDEN, Germany , June 17, 2015 ... Frankfurt Prime Standard: QIA) today launched new Investigator ® ... laboratories in the United States . The ... analyze multiple key genomic markers (short tandem repeats or STRs) ... Sensor to evaluate the quality of DNA in each sample, ...
(Date:6/16/2015)... June 16, 2015 Fingerprint Cards has ... sensors in the company,s portfolio from one of its module ... to mainly take place during the third quarter 2015. The ... Asia . Jörgen Lantto, CEO of FPC, ... the   growing interest from smartphone OEMs in integrating touch ...
(Date:6/12/2015)...  Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, announced the United States ... analyze and identify participants of a video visitation ... This system can: , Identify that ... sign-on process is actually the person participating in ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... to clean energy needs to be reformed if it ... according to two new articles by Stanford writers. ... massive energy system comes amid taxpayers, $500 million tab ... Solyndra, the global recession, government budget cuts and plunging ...
... WHAT: Cracking the Neural Code: Third Annual Aspen Brain Forum ... Academy of Sciences and The Aspen Brain Forum Foundation ... www.nyas.org/NeuralCode One of the greatest challenges in ... and neuronal circuits gives rise to higher order cognition and ...
... Raikhel , a distinguished professor of plant cell biology ... the most highly-cited researchers in plant science, has been elected ... (NAS) for her excellence in original scientific research. Elected ... 15 countries, Raikhel brings the number of current UC Riverside ...
Cached Biology News:America's clean energy policies need a reality check, say Stanford researchers 2America's clean energy policies need a reality check, say Stanford researchers 3America's clean energy policies need a reality check, say Stanford researchers 4UC Riverside plant cell biologist receives top scientific honor 2UC Riverside plant cell biologist receives top scientific honor 3
Mouse monoclonal [5H9] to RAD52 ( Abpromise for all tested applications). entrezGeneID: 5893 SwissProtID: P43351...
DNA sequencing - plasmids or PCR fragments, 3-7 working days service....
Purified anti-LAT...
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Biology Products: